Non-myeloablative allogeneic stem cell transplantation in patients with hematologic malignancies.
- Author:
Li-Ping SU
1
;
Zhen-Hua QIAO
;
Lian-Rong XU
;
Liang-Min MA
;
Bo JIANG
;
Qiu-Juan ZHU
;
Fang YE
;
Yu-Jing LU
;
Yue-E CUI
;
Lei ZHU
;
Li ZHANG
;
Xiang-Lan MA
;
Rong-Ping LI
Author Information
1. Department of Hematology, The Second Teaching Hospital of Shanxi Medical University, Taiyuan 030001, China. lpsu588@sohu.com
- Publication Type:Journal Article
- MeSH:
Adult;
Cytomegalovirus Infections;
etiology;
Female;
Graft vs Host Disease;
etiology;
Hematologic Neoplasms;
therapy;
Hematopoiesis;
Hematopoietic Stem Cell Transplantation;
adverse effects;
Humans;
Male;
Middle Aged;
Transplantation, Homologous
- From:
Journal of Experimental Hematology
2004;12(1):63-66
- CountryChina
- Language:Chinese
-
Abstract:
In order to investigate the clinical efficacy of non-myeloablative allogeneic stem cell transplantation (allo-NST) and related technology in patients with hematologic malignancies, twenty-six cases of hematological malignancies (10 AL, 14 CML, 2 MM patients) received NST following conditioning regimens with fludara + cyclophosphamide + ATG (14 cases) and busulfan or melphalan + cyclophosphamide + ATG (12 cases), G-CSF (600 micro g/d) or G-CSF (300 micro g/d) + GM-CSF (300 micro g/d) were used for mobilizing peripheral blood stem cell. A combination of cyclosporine A (CsA) and methotrexate (MTX) was administered for GVHD prophylaxis. Patients will be eligible for donor lymphocyte infusion (DLI) or donor stem cell infusion (DSI) given in graded increments according to the chimeric formation and clinical reaction. Generally the dose of the first infusion was 1 x 10(7)/kg at 4th week post-transplantation. The engraftment analysis included the detection of microsatellite short tandem repeats (STRs), Bcr/Abl fusion gene, Philadelphia chromosome, HLA-locus analysis, sex chromosome and ABO blood type or blood subtype. The results showed that 22 patients (84.62%) were engrafted, among which 18 patients were full donor chimerism (FDC) up to now. Acute GVHD occurred in 3/26 cases (11.54%). Chronic GVHD was diagnosed in 6 of 26 (23.07%) evaluable patients. The incidence of infection and hemorrhage was low and slight. It is concluded that allo-NST is a safe and effective therapeutic method for hematologic malignancies, but the related technology such as selection of indication, conditioning regimen and transplantation immunotherapy should be studied further.
